Pharmacoeconomic review report Sebelipase Alfa (Kanuma) (Alexion pharmaceuticals, Inc.)
Sebelipase alfa (Kanuma) is a recombinant form of the human lysosomal acid lipase (LAL) enzyme, and is indicated for the treatment of infants, pediatric, and adult patients diagnosed with LAL deficiency. The recommended starting dose in infants (less than six months of age) presenting with rapidly p...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | Inglés |
| Published: |
Ottawa (ON) :
CADTH
2018.
|
| Subjects: | |
| See on Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820267906719 |
| Summary: | Sebelipase alfa (Kanuma) is a recombinant form of the human lysosomal acid lipase (LAL) enzyme, and is indicated for the treatment of infants, pediatric, and adult patients diagnosed with LAL deficiency. The recommended starting dose in infants (less than six months of age) presenting with rapidly progressive LAL deficiency is 1 mg/kg administered as an intravenous infusion once weekly, with dose escalation to 3 mg/kg once weekly, based on clinical response. In pediatric and adult patients the recommended dose is 1 mg/kg administered as an intravenous infusion once every other week. The manufacturer submitted a price of |
|---|---|
| Physical Description: | 1 online resource |
